生物医药专刊

阿霉素诱导心脏毒性的发病机制与防治

展开
  • 北京大学人民医院,北京 100044

收稿日期: 2021-12-12

  网络出版日期: 2022-05-05

Pathogenic mechanism, prevention and treatment of doxorubicin-induced cardiotoxicity

Expand
  • Peking University People's Hospital, Beijing 100044, China

Received date: 2021-12-12

  Online published: 2022-05-05

摘要

阿霉素可治疗多种恶性肿瘤,但心脏毒性限制了其在临床的广泛应用。阿霉素诱导的心脏毒性的发病机制尚不明确,防治方面现有证据仍不足。文章梳理了有关阿霉素诱导心脏毒性致病机制与防治的最新研究进展,为进一步探索阿霉素诱导的心脏毒性提供更广泛的治疗思路和实验室依据。

本文引用格式

王青伟, 丁荣晶 . 阿霉素诱导心脏毒性的发病机制与防治[J]. 自然杂志, 2022 , 44(2) : 103 -108 . DOI: 10.3969/j.issn.0253-9608.2022.02.004

Abstract

Doxorubicin can be used to treat a variety of malignant tumors, but its wide clinical application is limited by doxorubicin-induced cardiotoxicity. The pathogenic mechanism of doxorubicin-induced cardiotoxicity remains unclear, and the available evidence
for prevention and treatment is still insufficient. This article reviews the pathogenic mechanisms, prevention and treatment of
doxorubicin-induced cardiotoxicity, aiming to provide a more extensive treatment idea and laboratory evidence for further exploration
of doxorubicin-induced cardiotoxicity.
文章导航

/